A decline in both revenues (more than 10% year-over-year) and EPS (also down 10%) is practically guaranteed to put investors off. What may help see Pfizer through is its future. The trailing 12-month price/earnings ratio is a large 23.68, while the future P/E ratio comes back to earth with a current print of 14.65.
The most recent analysts’ calls on the stock are also positive:
- Bernstein maintained its Outperform rating and boosted the price target from $38 to $39
- Jefferies initiated coverage in mid-June with an Overweight rating and a price target of $45
- Piper Jaffray initiated coverage in early June, also with an Overweight rating and $45 price target
Pfizer shares were recently trading at around $34.15 in the mid-afternoon on Monday. The consensus analyst price target is $38.25, and the 52-week range is $27.51 to $35.53. Pfizer has a 3.3% dividend yield, and its market cap is about $210.4 billion.The company has been in a state of flux following the the Zoetis spin-off and the pending Hospira acquisition. Analysts appear to believe that the $15 billion Hospira deal will give Pfizer a shot in the arm once the acquisition is final.
ALSO READ: 9 States with the Most Dangerous Weather
Cash Back Credit Cards Have Never Been This Good
Credit card companies are at war, handing out free rewards and benefits to win the best customers. A good cash back card can be worth thousands of dollars a year in free money, not to mention other perks like travel, insurance, and access to fancy lounges. See our top picks for the best credit cards today. You won’t want to miss some of these offers.
Flywheel Publishing has partnered with CardRatings for our coverage of credit card products. Flywheel Publishing and CardRatings may receive a commission from card issuers.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
